127 related articles for article (PubMed ID: 38536023)
21. TIM-3 polymorphism is involved in the progression of esophageal squamous cell carcinoma by regulating gene expression.
Cui SJ; Li Y; Zhou RM; Liu L; Cao SR; Huang X; Huo XR; Wang N
Environ Mol Mutagen; 2021 Apr; 62(4):273-283. PubMed ID: 33723872
[TBL] [Abstract][Full Text] [Related]
22. Association between CTLA-4 + 49A > G and - 318C > T single-nucleotide polymorphisms and susceptibility to thyroid neoplasm.
Abtahi S; Izadi Jahromi F; Dabbaghmanesh MH; Malekzadeh M; Ghaderi A
Endocrine; 2018 Oct; 62(1):159-165. PubMed ID: 30078171
[TBL] [Abstract][Full Text] [Related]
23. Higher frequency of the CTLA-4
Chen Y; Tan J; Huang S; Huang X; Huang J; Chen J; Yu Z; Lu Y; Weng J; Du X; Li Y; Zha X; Chen S
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e12-e18. PubMed ID: 31612643
[TBL] [Abstract][Full Text] [Related]
24. [Expression of Tim-3 on natural killer cells in patients with acute myeloid leukemia and its clinical significance].
Ma JF; Li CX; Wu DP; Sun ZL; Yan CL
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):755-758. PubMed ID: 31648478
[No Abstract] [Full Text] [Related]
25. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
Irani YD; Kok CH; Clarson J; Shanmuganathan N; Branford S; Yeung DT; Ross DM; Hughes TP; Yong ASM
Blood Adv; 2023 Jun; 7(11):2364-2374. PubMed ID: 36622326
[TBL] [Abstract][Full Text] [Related]
26. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
27. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients.
Wu K; Feng J; Xiu Y; Li Z; Lin Z; Zhao H; Zeng H; Xia W; Yu L; Xu B
Int Immunopharmacol; 2020 Mar; 80():106122. PubMed ID: 31955066
[TBL] [Abstract][Full Text] [Related]
28. Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype.
Shokrgozar N; Karimi M; Golmoghaddam H; Rezaei N; Moayed V; Sharifzadeh S; Arandi N
Ann Hematol; 2021 Oct; 100(10):2463-2469. PubMed ID: 34324022
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival.
Tu L; Guan R; Yang H; Zhou Y; Hong W; Ma L; Zhao G; Yu M
Int J Cancer; 2020 Jul; 147(2):423-439. PubMed ID: 31721169
[TBL] [Abstract][Full Text] [Related]
30. Tim-3 facilitates immune escape in benzene-induced acute myeloid leukemia mouse model by promoting macrophage M2 polarization.
Ning Q; Jian T; Cui S; Shi L; Jian X; He X; Zhang X; Li X
Ecotoxicol Environ Saf; 2023 Nov; 266():115532. PubMed ID: 37806131
[TBL] [Abstract][Full Text] [Related]
31. Correlation between CTLA-4 and CD40 gene polymorphisms and their interaction in graves' disease in a Chinese Han population.
Chen X; Hu Z; Liu M; Li H; Liang C; Li W; Bao L; Chen M; Wu G
BMC Med Genet; 2018 Sep; 19(1):171. PubMed ID: 30223781
[TBL] [Abstract][Full Text] [Related]
32. Association of CTLA-4 +49 A/G and CT60 Gene Polymorphism with Graves' Disease.
Fouad NA; Saeed AM; Mahedy AW
Egypt J Immunol; 2017 Jun; 24(2):63-70. PubMed ID: 29528580
[TBL] [Abstract][Full Text] [Related]
33. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
[TBL] [Abstract][Full Text] [Related]
34. The immune checkpoints Cytotoxic T lymphocyte antigen-4 and Lymphocyte activation gene-3 expression is up-regulated in acute myeloid leukemia.
Radwan SM; Elleboudy NS; Nabih NA; Kamal AM
HLA; 2020 Jul; 96(1):3-12. PubMed ID: 32189430
[TBL] [Abstract][Full Text] [Related]
35. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.
Assi R; Kantarjian H; Ravandi F; Daver N
Curr Opin Hematol; 2018 Mar; 25(2):136-145. PubMed ID: 29206680
[TBL] [Abstract][Full Text] [Related]
36. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
37. CTLA-4 polymorphisms: influence on transplant-related mortality and survival in children undergoing allogeneic hematopoietic stem cell transplantation.
Hammrich J; Wittig S; Ernst T; Gruhn B
J Cancer Res Clin Oncol; 2018 Mar; 144(3):587-592. PubMed ID: 29335768
[TBL] [Abstract][Full Text] [Related]
38. Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation.
Alahmari B; Alzahrani M; Al Shehry N; Tawfiq O; Alwasaidi T; Alhejazi A; Bakkar M; Al Behainy A; Radwi M; Alaskar A
JCO Glob Oncol; 2021 Jul; 7():1220-1232. PubMed ID: 34343012
[TBL] [Abstract][Full Text] [Related]
39. Occupational Low-Dose Radiation Affects the Expression of Immune Checkpoint of Medical Radiologists.
Wang C; Hao C; Dai K; Li Y; Jiao J; Niu Z; Xu X; Deng X; He J; Yao W
Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742351
[TBL] [Abstract][Full Text] [Related]
40. Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
Wu JL; Zhao J; Zhang HB; Zuo WW; Li Y; Kang S
Gynecol Oncol; 2020 Oct; 159(1):270-276. PubMed ID: 32694063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
